Skip to main content
. Author manuscript; available in PMC: 2019 Jan 1.
Published in final edited form as: J Immunol. 2017 Nov 17;200(1):130–138. doi: 10.4049/jimmunol.1700229

Figure 3. Ly6C+ macrophages are reduced in ankles and popliteal lymph nodes following treatment with infliximab.

Figure 3

Flow cytometric analysis demonstrating the effect of infliximab on leukocytes in (A) ankles and (B) pLNs, employing hTNF-Tg mice treated with infliximab or vehicle control, harvested at day 3. The gating strategy for ankle cells is the same as presented in Supplemental Figure 1C (n = 13 each group). Panel (C) represents the CCR7 expression on Ly6C- ankle macrophages, while panel (D) presents the percent CCR7 on Ly6C+ and Ly6C- macrophages before and after infliximab (n = 3 for each group). The gating strategy was the same as presented in Supplemental Figure 1D. All data presented were obtained employing 5-6 week old hTNF-Tg mice with arthritis. * represents p < 0.05, ** p <0.01 and *** p < 0.001 between the indicated groups.